Formulating for Dynamic Immune Resilience|September 10, 2026

LAC-Shield™ is a heat-killed Lactobacillus paracasei MCC1849, selected through strain screening for its ability to support immune health through the gut-brain axis.

LAC-Shield™ stimulates interleukin-12 production which contributes to communication between innate and adaptive immune cells, including the activation and differentiation of T cells. It has also been shown to activate plasmacytoid dendritic cells, which play a central role in early immune signaling for a rapid immune response.

Clinical Research

A randomized, double-blind, placebo-controlled study of 183 healthy young women who had experienced a common cold during the previous year found that LAC-Shield™ reduced the duration and frequency of subjective cold-like symptoms.

A 12-week study of 241 participants showed an improved adaptive immune response compared to placebo, as well as reports of positive mood maintenance, even under stressful conditions.

Additional clinical trials further support LAC-Shield’s immune health claims.

BB536® is a proprietary strain of Bifidobacterium longum with more than 50 years of research and commercial use. As a Human-Residential Bifidobacterium, BB536® is adapted to the human intestinal environment and overcomes typical probiotic fragility issues with its reliable stability in room temperatures. The ingredient supports a favorable microbial balance by promoting beneficial bacteria, including Bifidobacterium and Lactobacillus. It can also enhance the microbial fermentation of prebiotic substrates, supporting the production of short-chain fatty acids (SCFAs) associated with intestinal-barrier integrity and immune regulation.

Clinical Research

In a small randomized, double-blind study involving geriatric subjects, participants received BB536® for six weeks and were vaccinated against influenza during the third week. They then continued BB536® or received placebo during a 14-week observation period. No influenza cases were recorded among the 13 participants who continued BB536®, compared with five cases among the 14 participants receiving placebo. Fewer participants in the BB536® group experienced a fever of at least 100.4° (38°C) or required antibiotics. Neutrophil bactericidal activity and natural-killer-cell activity also increased during BB536® intake.

M-16V is a proprietary strain of Bifidobacterium breve, a species commonly found in the healthy infant gut. Originally isolated from a Japanese infant, this human-residential bifidobacterial strain has been studied extensively in newborns, including preterm and low-birth-weight infants.

Early establishment of bifidobacteria helps create a balanced intestinal environment which plays an important role in healthy digestive and immune development. M-16V is available for infant drops, powders, and probiotic supplements, as well as maternal wellness formulations.

Clinical Research

In a randomized, double-blind, placebo-controlled trial, 159 preterm infants born before 33 weeks of gestation received either 3 billion CFU of M-16V or placebo daily. Supplementation continued until a corrected gestational age of 37 weeks, with the primary microbiome assessment conducted after three weeks.

After three weeks, B. breve was detected in 91% of infants receiving M-16V compared with 38% of infants receiving placebo. The amount of fecal B. breve was also significantly higher in the M-16V group, demonstrating that supplementation promoted earlier and more consistent establishment of this beneficial species.

No probiotic-related adverse effects, probiotic sepsis, or deaths were reported. These findings support M-16V as a well-researched option for establishing a bifidobacteria-rich microbiome in preterm infants.

M-63 is a human-residential strain of Bifidobacterium longum subsp. infantis that is adapted to the intestinal environments of both infants and adults. Originally isolated from a healthy infant, M-63 has been studied for infant microbiome development, digestive health, stress response, and emotional well-being.

In infants, M-63 can utilize human milk oligosaccharides (HMOs), helping establish a Bifidobacterium-rich intestinal microbiome during early development. In adults, its interaction with the intestinal environment makes it relevant to formulations targeting digestive comfort and the gut-brain axis.

Because the gut microbiome communicates with the immune, nervous, and endocrine systems, supporting microbial balance may contribute to broader well-being.

Clinical Research

A three-month, randomized, double-blind, placebo-controlled trial evaluated Bifidobacterium longum subsp. infantis M-63 in 109 healthy full-term infants. Infants received either 1 billion CFU of M-63 daily or placebo beginning within 7 days of birth and continuing until 3 months of age.

M-63 supplementation significantly increased the relative abundance of Bifidobacterium compared with placebo at 1 week, 1 month, and 3 months of age. By 1 month, 94.6% of infants receiving M-63 had a Bifidobacterium-dominant microbiota compared with 51.0% in the placebo group. M-63 also promoted successful colonization of B. infantis, which was detected in 96.4% of supplemented infants versus 7.6% of controls.

Compared with placebo, infants receiving M-63 had significantly lower stool pH, higher fecal acetic acid concentrations, and higher fecal IgA levels at 1 month of age, suggesting enhanced gut microbial activity and support for mucosal immune function. Overall, the study suggests M-63 supports the establishment of a Bifidobacterium-dominant microbiome in early life, contributing to a healthier intestinal environment and supporting the maturation of immune function during a critical period of infant development.

NuCelium™ offers full-spectrum, certified organic mushroom powders cultivated indoors in Canada under controlled conditions. Its proprietary process retains the fruiting body, mycelium, extracellular metabolites, and myco-fermented matrix rather than isolating a single fraction of the mushroom.

This approach preserves beta-glucans, structural polysaccharides, fiber, and other naturally occurring compounds within a more complete compositional matrix. Each batch is DNA-verified and third-party tested to support identity, purity, and consistency.

For immune health formulations, five NuCelium™ species provide distinct but complementary positioning: